Literature DB >> 27874231

Stability of domain 4 of the anthrax toxin protective antigen and the effect of the VWA domain of CMG2 on stability.

Sireesha Mamillapalli1, Masaru Miyagi2, James G Bann1.   

Abstract

The major immunogenic component of the current anthrax vaccine, anthrax vaccine adsorbed (AVA) is protective antigen (PA). We have shown recently that the thermodynamic stability of PA can be significantly improved by binding to the Von-Willebrand factor A (VWA) domain of capillary morphogenesis protein 2 (CMG2), and improvements in thermodynamic stability may improve storage and long-term stability of PA for use as a vaccine. In order to understand the origin of this increase in stability, we have isolated the receptor binding domain of PA, domain 4 (D4), and have studied the effect of the addition of CMG2 on thermodynamic stability. We are able to determine a binding affinity between D4 and CMG2 (∼300 nM), which is significantly weaker than that between full-length PA and CMG2 (170-300 pM). Unlike full-length PA, we observe very little change in stability of D4 on binding to CMG2, using either fluorescence or 19 F-NMR experiments. Because in previous experiments we could observe a stabilization of both domain 4 and domain 2, the mechanism of stabilization of PA by CMG2 is likely to involve a mutual stabilization of these two domains.
© 2016 The Protein Society.

Entities:  

Keywords:  CMG2; anthrax; binding; protective antigen; stability

Mesh:

Substances:

Year:  2017        PMID: 27874231      PMCID: PMC5275732          DOI: 10.1002/pro.3087

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  30 in total

1.  Sortase-conjugation generates a capsule vaccine that protects guinea pigs against Bacillus anthracis.

Authors:  Gabriella Garufi; Ya-Ting Wang; So-Young Oh; Hannah Maier; Dominique M Missiakas; Olaf Schneewind
Journal:  Vaccine       Date:  2012-03-23       Impact factor: 3.641

2.  Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.

Authors:  Elizabeth K Leffel; James S Bourdage; E Diane Williamson; Matthew Duchars; Thomas R Fuerst; Peter C Fusco
Journal:  Clin Vaccine Immunol       Date:  2012-06-13

3.  Determination of pKa values of individual histidine residues in proteins using mass spectrometry.

Authors:  Masaru Miyagi; Takashi Nakazawa
Journal:  Anal Chem       Date:  2008-07-30       Impact factor: 6.986

4.  Crystal structure of a complex between anthrax toxin and its host cell receptor.

Authors:  Eugenio Santelli; Laurie A Bankston; Stephen H Leppla; Robert C Liddington
Journal:  Nature       Date:  2004-07-04       Impact factor: 49.962

5.  Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions.

Authors:  Kenneth A Bradley; Jeremy Mogridge; G Jonah; A Rainey; Sarah Batty; John A T Young
Journal:  J Biol Chem       Date:  2003-09-24       Impact factor: 5.157

6.  Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.

Authors:  M J Rosovitz; Peter Schuck; Mini Varughese; Arun P Chopra; Varsha Mehra; Yogendra Singh; Lisa M McGinnis; Stephen H Leppla
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

7.  Domain 4 of the anthrax protective antigen maintains structure and binding to the host receptor CMG2 at low pH.

Authors:  Alexander S Williams; Scott Lovell; Asokan Anbanandam; Rahif El-Chami; James G Bann
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

8.  Divalent metal ion coordination by residue T118 of anthrax toxin receptor 2 is not essential for protective antigen binding.

Authors:  Heather M Scobie; John A T Young
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

9.  Long-range stabilization of anthrax protective antigen upon binding to CMG2.

Authors:  Vennela Mullangi; Sireesha Mamillapalli; David J Anderson; James G Bann; Masaru Miyagi
Journal:  Biochemistry       Date:  2014-09-15       Impact factor: 3.162

10.  Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.

Authors:  M Gordon Joyce; Baoshan Zhang; Li Ou; Man Chen; Gwo-Yu Chuang; Aliaksandr Druz; Wing-Pui Kong; Yen-Ting Lai; Emily J Rundlet; Yaroslav Tsybovsky; Yongping Yang; Ivelin S Georgiev; Miklos Guttman; Christopher R Lees; Marie Pancera; Mallika Sastry; Cinque Soto; Guillaume B E Stewart-Jones; Paul V Thomas; Joseph G Van Galen; Ulrich Baxa; Kelly K Lee; John R Mascola; Barney S Graham; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2016-08-01       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.